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ABSTRACT
Objectives To assess the effects of non- steroidal 
anti- inflammatory drugs (NSAIDs) in patients with viral 
respiratory infections on acute severe adverse outcomes, 
healthcare utilisation, quality of life and long- term 
survival.
Design Rapid systematic review.
Participants Humans with viral respiratory infections, 
exposed to systemic NSAIDs.
Primary outcomes Acute severe adverse outcomes, 
healthcare utilisation, quality of life and long- term 
survival.
Results We screened 10 999 titles and abstracts and 
738 full texts, including 87 studies. No studies addressed 
COVID-19, Severe Acute Respiratory Syndrome or Middle 
East Respiratory Syndrome; none examined inpatient 
healthcare utilisation, quality of life or long- term survival. 
Effects of NSAIDs on mortality and cardiovascular events 
in adults with viral respiratory infections are unclear 
(three observational studies; very low certainty). Children 
with empyema and gastrointestinal bleeding may be 
more likely to have taken NSAIDs than children without 
these conditions (two observational studies; very low 
certainty). In patients aged 3 years and older with acute 
respiratory infections, ibuprofen is associated with a 
higher rate of reconsultations with general practitioners 
than paracetamol (one randomised controlled trial (RCT); 
low certainty). The difference in death from all causes and 
hospitalisation for renal failure and anaphylaxis between 
children with fever receiving ibuprofen versus paracetamol 
is likely to be less than 1 per 10 000 (1 RCT; moderate/high 
certainty). Twenty- eight studies in adults and 42 studies in 
children report adverse event counts. Most report that no 
severe adverse events occurred. Due to methodological 
limitations of adverse event counts, this evidence should 
be interpreted with caution.
Conclusions It is unclear whether the use of NSAIDs 
increases the risk of severe adverse outcomes in patients 
with viral respiratory infections. This absence of evidence 
should not be interpreted as evidence for the absence 
of such risk. This is a rapid review with a number of 
limitations.
PROSPERO registration number CRD42020176056.
BACKGROUND
Non- steroidal anti- inflammatory drugs 
(NSAIDs) are among the most commonly 
used drugs, and have a wide range of uses, 
including treatment of acute and chronic 
pain, fever and inflammation. NSAIDs include 
unselective cyclo- oxygenase (COX) inhibi-
tors (eg, ibuprofen, aspirin, diclofenac and 
naproxen) as well as selective COX 2 inhibi-
tors or cyclo- oxygenase-2 inhibitors (eg, cele-
coxib, rofecoxib and etoricoxib). NSAIDs are 
associated with a number of adverse effects, 
in particular when used at higher doses, over 
longer periods of time, in the elderly and in 
patients with relevant comorbidities.1–3 Well- 
established adverse effects include gastro-
intestinal ulcers and bleeding1 and renal 
damage,4 as well as elevated cardiovascular 
risks for some NSAIDs.1 5 These potential 
harms must be balanced with the potential 
therapeutic benefits of NSAIDs.
Strengths and limitations of this study
 ► We conducted a rapid systematic review following 
Cochrane rapid review guidance and the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses guideline.
 ► We systematically searched three databases and 
conducted forward- citation and backward- citation 
searches.
 ► We followed a prespecified protocol, and clearly 
state where we deviated from it.
 ► This is a rapid review, and we applied less quality 
controls than in the reviews we normally conduct.
 ► The review is limited to studies in patients with 
viral respiratory infections and conditions com-
monly caused by respiratory viruses; we excluded 
studies on adverse effects of non- steroidal anti- 
inflammatory drugs in patients with bacterial respi-
ratory infections, which have been summarised in 
existing reviews.
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Acute viral respiratory infections, in particular influ-
enza, are associated with an elevated risk for a number 
of severe adverse outcomes, in particular in the elderly 
and in patients with relevant comorbidities. This includes 
myocardial infarction,6 ischaemic and haemorrhagic 
stroke,7–9 as well as deep vein thrombosis and pulmonary 
embolism.10 Preventing influenza through vaccination is 
therefore an effective way to reduce cardiovascular events 
and mortality.11 Acute viral respiratory infections can also 
trigger a worsening of underlying chronic conditions, 
including chronic obstructive pulmonary disease12 and 
heart failure.13 14
Recently, concerns have been raised that in patients 
with COVID-19 and other viral respiratory infections, 
the use of NSAIDs may be associated with an addition-
ally increased risk for severe adverse outcomes, above and 
beyond the known risks of NSAIDs alone and of acute 
viral respiratory infections alone.15–17 In particular, the 
question has been raised whether the combined expo-
sure to NSAIDs and acute viral respiratory infections 
(COVID-19 in particular) leads to: (1) specific adverse 
events that likely would not occur due to either exposure 
alone; (2) a worsening of the course of the infection or 
(3) an increase in the rate and severity of the known side 
effects of NSAIDs.
These concerns, notably regarding COVID-19, led the 
WHO to request the present rapid review. Specifically, 
the review aims to assess the effects of systemic NSAIDs in 
patients with viral respiratory infections on acute severe 
adverse events (including mortality, acute respiratory 
distress syndrome, acute organ failure and opportunistic 
infections), acute healthcare utilisation (including hospi-
talisation, intensive care unit admission, supplemental 
oxygen therapy and mechanical ventilation), as well as 
explicit quality of life measures and long- term survival.
METHODS
Protocol registration
The review was registered with PROSPERO and the Open 
Science Framework ( osf. io/ snrp4). Methods are based 
on Cochrane Rapid Review guidance.18 Reporting follows 
the Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses (PRISMA) guideline.
Search strategy and selection criteria
We searched MEDLINE, EMBASE and the WHO 
COVID-19 database19 up to 31 March 2020. We conducted 
forward- citation and backward- citation searches in Scopus 
using references of existing reviews and included studies. 
Our full search strategy is shown in the online supple-
mental appendix.
After removal of duplicate studies, titles and abstracts of 
all identified records were screened by one review author 
to select records meeting our inclusion criteria. Subse-
quently, full texts were screened by one review author. 
Twenty per cent of all titles and abstracts, and 50% of all 
full texts were screened by a second review author. We 
used Rayyan, a web- based application for title and abstract 
screening.20 During full- text screening, we documented 
the reasons for exclusion.
We included studies conducted in humans of any age 
with viral respiratory infections or conditions commonly 
caused by respiratory viruses and exposed to systemic 
NSAIDs of any kind, reporting on acute severe adverse 
events, acute healthcare utilisation, explicit quality of 
life measures or long- term survival. We included studies 
reporting primary empirical data on at least 10 partici-
pants, except for studies on COVID-19, Severe Acute 
Respiratory Syndrome (SARS) and Middle East Respira-
tory Syndrome (MERS), where studies of any size were 
eligible. Tables 1 and 2 provide detailed inclusion and 
exclusion criteria.
We included studies in which at least 50% of all patients 
in one of the study groups (intervention or control group 
for randomised controlled trials (RCTs), and cases or 
controls for case–control studies) met our inclusion 
criteria (ie, were adults, had a relevant infection or condi-
tion, and were exposed to NSAIDs).
We excluded studies in which patients received antibi-
otics as part of the intervention, taking antibiotic treat-
ment as a proxy for bacterial infection. We did, however, 
include studies in which varying numbers of partici-
pants received antibiotics independent of the interven-
tion over the course of the study.21 We also included one 
study in patients with confirmed influenza infection 
who received an antibiotic as part of their initial treat-
ment regime.22
Data analysis
One review author extracted data and assessed risk of bias 
of included studies using a pretested data extraction form 
(see online supplemental appendix). We used the Tool to 
Assess Risk of Bias in Case–Control Studies developed by 
the Clarity Group at McMaster University for case–control 
and case–crossover studies,23 and the Cochrane risk of 
bias tool adapted by the Cochrane Effective Practice 
and Organisation of Care group for all remaining study 
designs.24 We applied Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) to 
assess the certainty of evidence, rating evidence as high, 
moderate, low or very low certainty.25
Due to time constraints and the large number of 
studies identified, we decided post hoc to restrict full 
evidence synthesis to studies in adults, as well as to studies 
in children using study designs most capable of detecting 
rare severe adverse events (ie, case–control studies and 
large RCTs with >1000 participants) as these studies best 
addressed the commissioned review question. For the 
remaining studies in children, we mapped the evidence, 
that is, we extracted and tabulated data on key study char-
acteristics and adverse outcomes, but did not assess risk of 
bias and certainty of evidence.
We had originally planned to extract data on two sets of 
secondary outcomes (laboratory measures and imaging 
findings), but decided that this was not feasible within 
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the timeframe of the review. We had intended to under-
take meta- analyses and present forest plots of sufficiently 
similar studies. This was not feasible in view of substan-
tial heterogeneity in the interventions and outcomes 
assessed. We therefore summarised findings narratively 
and through tables.
We extracted and report all measures of treatment 
effect for the primary outcomes prespecified in our 
protocol. For dichotomous outcomes this includes risk 
ratios (RRs) and ORs. We extracted and report adjusted 
results as provided by the included studies. We included 
95% CIs when these were reported by primary studies.
Table 1 Inclusion criteria
Population Humans of any age with acute viral respiratory 
infections, with or without comorbidities (eg, 
cardiovascular disease, diabetes mellitus, COPD, asthma)
Patients with COVID-19/SARS- CoV-2
Patients with SARS/MERS
Patients with other coronavirus infections
Patients with other acute viral respiratory infections, including 
influenza, parainfluenza and rhinovirus infections
Patients with conditions commonly caused by respiratory 
viruses, including children with fever and patients of any age with 
upper respiratory tract infections, including the common cold, 
pharyngitis, laryngitis, sore throat and tonsillitis, unless specified as 
being of bacterial aetiology or treated with antibiotics
Intervention/ 
exposure
Non- steroidal anti- inflammatory drug (NSAID) intake 
prior or during the acute infection, including oral, 
intravenous and intramuscular NSAIDs and NSAIDs 
as suppositories taken or administered for any reason 
(including treatment of underlying conditions, and 
treatment of fever, pain and other acute symptoms)
Unselective COX inhibitors: ibuprofen, aspirin (acetylsalicylate), 
diclofenac, naproxen, indomethacin, ketoprofen, etc
Selective COX 2 inhibitors: celecoxib, rofecoxib, etoricoxib, 
lumiracoxib, valecoxib, etc
Comparison No or different NSAID No NSAID (including other antipyretic and analgesic drugs, for 
example, paracetamol/acetaminophen)
Different dose or application of NSAID
Different NSAID (eg, aspirin vs ibuprofen)
Outcomes Acute severe adverse events, acute healthcare 
utilisation and longer- term effects
Acute severe adverse events:
 ► Mortality
 ► Acute respiratory distress syndrome
 ► Acute organ failure (including acute renal failure)
 ► Cardiovascular events
 ► Opportunistic infections
 ► Severe acute allergic and hypersensitivity reactions
 ► Other, as reported
Acute healthcare utilisation:
 ► Rate and length of hospitalisation
 ► Rate and length of intensive care unit utilisation
 ► Rate and length of supplemental oxygen therapy
 ► Rate, length and type of mechanical ventilation (invasive vs 
non- invasive)
 ► Other, as reported
Longer- term effects:
 ► Explicit quality of life measures
 ► Long- term survival





Case series with >10 patients
Case series with <10 patients (only for COVID-19, SARS and 
MERS)
COPD, chronic obstructive pulmonary disease; COX, cyclo- oxygenase; MERS, Middle East Respiratory Syndrome; SARS, Severe Acute Respiratory 
Syndrome.
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Availability of data and materials
The data supporting the conclusions of this article are 
included within the article and its additional file.
Role of the funding source
This review was funded through staff positions and 
university funds at the Ludwig- Maximilians- Universität 
(LMU) Munich, Germany. The review question was set 
by the WHO, who requested this review from the Chair of 
Public Health and Health Services Research at the LMU 
Munich in its capacity as a WHO Collaborating Centre 
for Evidence- Based Public Health. The authors alone are 
responsible for the views expressed in this article and they 
do not necessarily represent the decisions, policy or views 
of the WHO.
Patient and public involvement
Patients and the public were not involved in this study.
RESULTS
Results of the search
The PRISMA flow chart is shown in figure 1, and the 
search log is shown in the online supplemental appendix. 
Through database and forward- citation and backward- 
citation searches we identified 10 999 unique records. Of 
these, we excluded 10 196 at title and abstract screening 
stage, leaving 803 studies to be assessed as full texts. We 
were able to locate and assess the full texts for 738 studies. 
Overall, 87 studies met the eligibility criteria and were 
included in our review.
We included 72 RCTs, 7 cohort studies, 3 case–cross-
over studies, 3 non- RCTs (NRCTs), 1 case–control study 
and 1 case series. The total number of participants was 
172 381 (median: 174, range: 20–83 915). The median 
follow- up was 3 days (range: 1 hour to 11 months). We 
did not identify any study on COVID-19, SARS or MERS 
meeting the eligibility criteria. All studies related to other 
acute viral infections, or to conditions, such as upper 
respiratory tract infections, that are commonly caused by 
respiratory viruses.
We included 39 studies in our evidence synthesis and 
48 studies in our evidence mapping. Studies included 
in the evidence synthesis comprised 28 RCTs, 3 cohort 
studies26–28 and 2 case–crossover studies8 9 in adults, and 
3 case–control studies29 30 and 4 studies reporting on 1 
RCT in children.31–34 One retrospective cohort study27 
and one RCT21 included both adults and children. The 
latter included participants aged 3 years and older, and 
did not report results separately for adults and children. 
With the majority being adults, we included this study in 
the evidence synthesis for adults. We assessed most of the 
studies to be at high or unclear risk of bias in at least one 
domain. Risk of bias of case–control and case–crossover 
studies is shown in figure 2, and risk of bias of all other 
study designs in figure 3. Studies included in evidence 
mapping comprised 39 RCTs, 4 cohort studies, 4 NRCTs 
and 1 case series in children. Details on the popula-
tion, intervention and comparison, outcomes and study 
designs of included studies are provided in the online 
supplemental appendix.
Findings for adults
Summary of findings for the effects of NSAIDs on mortality 
and cardiovascular events in adults with viral respiratory 
infections is shown in table 3. Effects on the rate of recon-
sultations with general practitioners are shown in table 4.
One retrospective registry- based cohort study in 683 
adults with a follow- up of 60 days reports effects on 
mortality.27 Results indicate that the effects of NSAIDs 
on mortality in critically ill adults with influenza during 
the 2009/2010 H1N1 influenza pandemic are unclear 
(adjusted RR (aRR): 0.9, 95% CI: 0.5 to 1.6). The CI for 
this effect estimate is large and includes the possibility 
of a negative, null or positive effect. This evidence was 
graded as very low certainty. The same conclusion (very 
low certainty evidence) is suggested for a subgroup anal-
ysis for aspirin only (data shown in online supplemental 
appendix table 1).
Two case–crossover studies in 9793 patients with 
myocardial infarction and 29 518 patients with ischaemic 
or haemorrhagic stroke assessed effects on cardiovascular 
Table 2 Exclusion criteria
Population  ► Patients with acute bacterial respiratory infections
 ► Patients with non- respiratory viral infections
 ► Patients with haemorrhagic fevers (including 
dengue and ebola)
 ► Patients with infections treated with antibiotics
 ► Patients with pneumonia, unless specified 
explicitly as being of viral aetiology
Intervention /
exposure
 ► NSAIDs no longer approved or marketed in key 
markets (eg, US, Europe)
 ► Non- systemic/topical application of NSAIDs, 
including lozenges, sprays and microgranules
 ► Corticosteroids
 ► Paracetamol (acetaminophen)
Outcomes  ► Adverse outcomes of NSAIDs occurring 
independently of viral respiratory infections, 
including gastrointestinal effects and renal 
damage associated with long- term use of any 
NSAID, and cardiovascular risks due to selective 
cyclo- oxygenase 2 inhibitors and diclofenac, as 
these are well established
 ► Allergic and hypersensitivity reactions occurring 
in general, that is, in the absence of viral 
respiratory infections
 ► Reye’s syndrome and Kawasaki syndrome, as 
these represent well- studied conditions outside 
the scope of this review




 ► Non- empirical studies (eg, commentaries)
 ► Animal studies
 ► Mechanistic data
NSAIDs, non- steroidal anti- inflammatory drugs.
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events.8 9 Both studies report multiple indirect compar-
isons, comparing adults without acute respiratory infec-
tion and not exposed to NSAIDs to: (1) adults exposed 
to both an acute respiratory infections and NSAIDs; (2) 
adults with an acute respiratory infection but not exposed 
to NSAIDs and (3) adults without an acute respiratory 
infection but exposed to NSAIDs. Both studies report 
higher ORs for the combined exposure to NSAIDs and 
acute respiratory infections than for the exposure to 
either acute respiratory infections or NSAIDs alone (see 
table 4). As the CIs of these ORs overlap we assessed the 
effect of NSAIDs on cardiovascular events in adults with 
acute respiratory infections as unclear (very low certainty 
evidence). Both studies report subgroup analyses based 
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta- Analyses flow chart.
Figure 2 Risk of bias of case–control and case–crossover studies. ARI, acute respiratory infection; NSAID, non- steroidal anti- 
inflammatory drug.
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on dosage and type of application as well as type of NSAID. 
The subgroup analyses for specific NSAIDs suggest that 
the differences in the ORs presented in table 4 may be 
driven by a subset of NSAIDs with a known elevated 
cardiovascular risk profile (COX-2 inhibitors, diclofenac 
and mefenamic acid). However, CIs overlap and include 
the possibility of negative, null or positive effects (very low 
certainty evidence) (see online supplemental appendix 
table 1).
We identified 28 RCTs21 22 35–60 and 2 cohort studies26 28 
reporting counts of adverse events. Most of these studies 
were of short duration (follow- up: 2 hours to 30 days, 
median: 4.5 days). Most studies were small (median 
number of participants: 209, range: 30–2341). Sixteen 
studies report that no or no severe adverse effects were 
observed.22 35 37 39 41 42 44 47–49 52–56 59 Three studies report 
that adverse effects, classified as severe or serious by the 
study authors, occurred, including dyspepsia, nausea and 
urticaria,28 as well as single cases of syncopation43 pneu-
monia, meningitis and peritonsillar abscess.21 Eleven 
studies report mild or moderate adverse events, but do 
not mention severe adverse events.26 36 38 40 45 46 50 51 57 58 60 
The most commonly reported mild or moderate adverse 
events were abdominal pain,26 38 40 46 50 51 58 drowsiness 
or lightheadedness,36 40 45 50 57 and nausea.26 40 60 Due to 
the inherent methodological limitations of adverse event 
counts,61 and the small sample size and short follow- up 
of most of these studies, this evidence was not assessed 
with GRADE, and should be interpreted with caution. 
One study reporting effects on adverse event counts also 
reports effects on the rate of reconsultations, presented 
below.21
One RCT in 889 patients aged 3 years or older with 
a follow- up of 4 weeks assessed effects on the rate of 
Figure 3 Risk of bias of studies other than case–control and case–crossover studies.
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reconsultations with general practitioners.21 Data on 
595 patients were included in the analyses. Results indi-
cate that in patients with acute respiratory infections 
ibuprofen is associated with a higher rate of reconsulta-
tions for new or unresolved symptoms or complications 
than paracetamol (acetaminophen) (OR 1.7, 95% CI: 1.1 
to 2.4). The study reports that ‘(m)ost of the 17 ‘compli-
cations’ recorded were not serious’.21 This evidence was 
considered to be of low certainty due to study limitations 
and indirectness of evidence.
Findings for children
Summary of findings for effects of NSAIDs on mortality 
and risk for empyema, gastrointestinal bleeding, death 
from all causes and hospitalisation in children is shown in 
online supplemental appendix tables 2 and 3.
One cohort study in 838 children (mean age: 7 years) 
with a follow- up of 60 days reports effects on mortality.27 
Results indicate that the effects of NSAIDs on mortality 
in critically ill children with H1N1 influenza are unclear 
(aRR 1.5, 95% CI: 0.7 to 3.2; very low certainty evidence).
One matched case–control study in 166 children 
aged 3–15 years with acute viral infections reports 
effects on risk for empyema (follow- up: 15 days).30 One 
case–crossover study in 177 children (aged 2 months to 
16 years) with fever reports effects on gastrointestinal 
bleeding (follow- up: 7 days).29 Results indicate that 
children with empyema and gastrointestinal bleeding 
may be more likely to have been exposed to NSAIDs 
than children without these conditions (adjusted OR 
(aOR) for empyema: 2.8, 95% CI: 1.4 to 5.6; aOR for 
gastrointestinal bleeding: 8.2, 95% CI: 2.6 to 26.0; very 
low certainty evidence).29 30
Four studies on one RCT including 83 915 chil-
dren report effects on death from all causes and risk 
for hospitalisation (follow- up: 4 weeks), comparing 
ibuprofen with acetaminophen (paracetamol).31–34 
The study had 80% power to detect a 0.2% difference 
in hospitalisation for any cause, and differences of 1 
per 10 000 for hospitalisation for acute gastrointestinal 
bleeding, acute renal failure and anaphylaxis. Our 
Table 3 Use of NSAIDs compared with no use of NSAIDs in adults with acute respiratory infections (ARIs)
Patient or population: adults with ARIs
Intervention: use of NSAIDs
Comparison: no use of NSAIDs








Follow- up: 60 days following 
intensive care unit admission or until 
death or hospital discharge
Epperly 2016









Follow- up: exposure in case 
period (7 days prior to event) was 
compared with control period (365 
days prior to case period)
Wen 2018
Compared with no use of NSAIDs in adults without ARI (baseline):
Risk associated with NSAID use and ARI episode: aOR=2.27 (95% CI: 
2.00 to 2.58)
Risk associated with ARI episode: aOR=2.11 (95% CI: 1.91 to 2.34)
Risk associated with NSAID use: aOR=1.38 (95% CI: 1.30 to 1.46)






Follow- up: exposure in case 
period (7 days prior to event) was 
compared with control period (365 
days prior to case period)
Wen 2018
Compared with no use of NSAIDs in adults without ARI (baseline):
Risk associated with NSAID use and ARI episode: aOR=2.28 (95% CI: 
1.71 to 3.02)
Risk associated with ARI episode: aOR=1.63 (95% CI: 1.31 to 2.03)







Follow- up: exposure in case 
period (7 days prior to event) was 
compared with control period (365 
days prior to case period)
Wen 2017
Compared with no use of NSAIDs in adults without ARI (baseline):
Risk associated with NSAID use and ARI episode: aOR=3.41 (95% CI: 
2.80 to 4.16)
Risk associated with ARI episode: aOR=2.65 (95% CI: 2.29 to 3.06)





GRADE Working Group grades of evidence: high certainty—we are very confident that the true effect lies close to that of the estimate of the 
effect; moderate certainty—we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, 
but there is a possibility that it is substantially different; low certainty—our confidence in the effect estimate is limited: the true effect may be 
substantially different from the estimate of the effect; very low certainty—we have very little confidence in the effect estimate: the true effect is likely 
to be substantially different from the estimate of effect.
*All studies included for this comparison were non- randomised; thus each body of evidence started the GRADE assessment as low certainty.
†Downgraded by 1 level for imprecision.
aOR, adjusted OR; aRR, adjusted risk ratio; GRADE, Grading of Recommendations Assessment, Development and Evaluation; NSAIDs, non- steroidal 
anti- inflammatory drugs.
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assessment of the certainty of evidence for differences 
between the ibuprofen and the acetaminophen group 
is based on these thresholds for relevant differences. 
Results indicate that the difference in the rate of death 
from all causes and of hospitalisation for acute renal 
failure and anaphylaxis is likely to be smaller than 1 
per 10 000, that the difference in hospitalisation for 
acute gastrointestinal bleeding is likely to be smaller 
than 2 per 10 000, and the difference in hospitalisation 
for any cause less than 20 per 10 000 (moderate to high 
certainty evidence).
Forty- two RCTs, five cohort studies and one case 
series in children report adverse event counts. Most 
studies report some mild or moderate adverse effects 
but do not mention severe adverse effects (24 studies). 
Ten studies explicitly report that there had been no 
severe adverse effects during the follow- up period. In 
six studies, severe adverse effects were observed. The 
remaining eight studies state that there had been no 
adverse effects but do not specify their severity. Due 
to the inherent methodological limitations of adverse 
event counts, and the small sample size and short 
follow- up of most of these studies, this evidence should 
be interpreted with caution.
DISCUSSION
We identified 33 studies in adults examining adverse 
outcomes of NSAIDs in patients with viral respiratory 
infections or conditions commonly caused by respira-
tory viruses. None of these studies was in patients with 
COVID-19, SARS or MERS. Therefore, all evidence 
included in this review should be considered as indi-
rect evidence for the use of NSAIDs in patients with 
COVID-19. Potential adverse effects of NSAIDs specific 
to COVID-19, SARS or MERS could therefore not be 
explored in our review.15 62 Evidence obtained for 
adults was of very low to low certainty, and should be 
interpreted with caution. We did not find conclusive 
evidence for relevant effects of NSAIDs on mortality 
or other severe acute adverse outcomes in adults with 
viral respiratory infections. Low certainty evidence 
from one RCT indicates that in participants aged 3 
years and older with respiratory infections ibuprofen 
compared with acetaminophen (paracetamol) is 
associated with a higher rate of reconsultations with 
general practitioners.21
We identified 56 eligible studies in children. Most of these 
were small and of short duration, and provide only limited 
evidence on severe adverse effects. One large RCT in chil-
dren provides moderate to high certainty evidence that the 
difference in the rate of death from all causes and of hospi-
talisation for acute renal failure and anaphylaxis is likely to 
be smaller than 1 per 10 000, that the difference in hospi-
talisation for acute gastrointestinal bleeding is likely to be 
smaller than 2 per 10 000, and the difference in hospitalisa-
tion for any cause less than 20 per 10 000.31–34
We did not identify any studies reporting on measures 
of inpatient healthcare utilisation, long- term survival or 
explicit quality of life measures.
This is a rapid review, conducted over 2 weeks, with a 
number of limitations:
 ► Searches were limited to three databases, that is, 
MEDLINE, EMBASE and the WHO COVID-19 
database, complemented with forward- citation and 
backward- citation searches. We did not search for 
or include sources of grey literature or preprints, 
and considered only studies published in English or 
German.
 ► Screening criteria and guidance were refined and 
calibrated while screening was underway, and only 
20% of titles and abstracts and 50% of full texts were 
screened in duplicate.
 ► Data extraction and risk of bias assessment were done 
by one review author only. To account for potential 
errors, all data presented in tables or figures as part of 
the evidence synthesis were checked for their correct-
ness by a second review author.
 ► Risk of bias assessment and full evidence synthesis 
was limited to studies in adults and to those studies in 
Table 4 Use of ibuprofen versus paracetamol in 
participants aged ≥3 years with acute respiratory tract 
infections
Patient or population: participants aged ≥3 years with acute 
respiratory tract infections
Intervention: use of ibuprofen
Comparison: use of paracetamol

















with use of 
ibuprofen: aRR 







GRADE Working Group grades of evidence: high certainty—
we are very confident that the true effect lies close to that of the 
estimate of the effect; moderate certainty—we are moderately 
confident in the effect estimate: the true effect is likely to be 
close to the estimate of the effect, but there is a possibility that 
it is substantially different; low certainty—our confidence in the 
effect estimate is limited: the true effect may be substantially 
different from the estimate of the effect; very low certainty—we 
have very little confidence in the effect estimate: the true effect 
is likely to be substantially different from the estimate of effect.
*Downgraded evidence by 1 level for study limitations: lack of 
blinding.
†Downgraded evidence by 1 level for indirectness: advice to use 
versus direct use.
aRR, adjusted risk ratio; GRADE, Grading of Recommendations 
Assessment, Development and Evaluation; RCT, randomised 
controlled trial.
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children most capable of detecting rare severe adverse 
events (ie, case–control studies and large RCTs). The 
decision to exclude other studies in children from 
evidence synthesis was taken post hoc.
 ► All steps of the review process were undertaken rapidly, 
with fewer quality control measures than during the 
systematic reviews we usually conduct.
 ► We were unable to undertake all the subgroup anal-
yses foreseen in our protocol: many were not feasible 
due to too much heterogeneity between studies, for 
others (eg, subgroup analyses by age or sex) we lacked 
the time.
The evidence identified in this review is also character-
ised by a number of limitations:
 ► We included not only studies in patients with 
confirmed viral respiratory infections, but also studies 
in patients with conditions commonly caused by 
respiratory viruses, such as upper respiratory tract 
infections and fever in children. It is likely that not 
all participants of these studies had viral respiratory 
infections.
 ► We did not consider studies on patients with bacte-
rial infections; these can occur as a super- infection 
in patients with viral respiratory infections. Potential 
adverse effects of NSAIDs in patients with bacterial 
infections and conditions commonly caused by bacte-
rial infections, including community- acquired pneu-
monia, have been summarised in existing reviews63 
and were beyond the scope of this rapid review.
 ► NSAIDs constitute a diverse group of drugs with 
diverging risk profiles for different populations and 
conditions. Not all studies distinguished between 
different types of NSAIDs. Some of the older studies 
are likely to have included patients taking NSAIDs 
that are no longer available on the market due to 
their known side effects.
 ► Some studies provided only indirect comparisons, 
which can be informative, but do not provide effect 
estimates for the actual comparison of interest, that 
is, NSAID use versus no NSAID use among individuals 
with a viral respiratory infection.8 9
 ► We identified only one RCT that included a suffi-
ciently large number of participants to identify rare 
severe adverse events.31–34 The remaining evidence 
derives from smaller RCTs, which are underpowered 
for detecting rare severe adverse events, and from 
case–control and cohort studies with methodological 
limitations.
Conclusions
We did not find conclusive evidence showing that NSAIDs 
in patients with viral respiratory infections are associated 
with additional risks for severe acute adverse outcomes, 
above and beyond the known risks associated with NSAIDs 
alone and viral respiratory infections alone. This absence 
of evidence should not be interpreted as evidence for the 
absence of such risks. Most of the evidence was of very low 
to low certainty, and should be interpreted with caution. 
To improve the evidence base, future studies should use 
robust study design, sufficiently large sample sizes and 
follow- up periods, and follow relevant reporting guide-
lines. When using NSAIDs, existing guidance should be 
considered, including approved product information for 
specific NSAIDs and relevant clinical guidelines.
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